Back to search results

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Abroad (travel likely)RecruitingPHASE3

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Parkway Medical Center, Birmingham, Alabama, United States

    Contact: Study coordinator (Trina Gray) · graytrina1989@gmail.com · +1 205 815 5000
    Contact: Principal Investigator (James Gregory Sullivan)

  • Clinical Research Inst of Arizona, Sun City West, Arizona, United States

    Contact: Study coordinator (Georgina Lopez-Wood) · glopezwood@criofaz.com · +1 623 223 1580
    Contact: Principal Investigator (Jalal Abbas)

  • National Heart Institute, Beverly Hills, California, United States

    Contact: Study coordinator (Nayeli Aguillon) · naguillon@nationalheartinstitute.org · +1 301 289 5221
    Contact: Principal Investigator (Norman Lepor)

  • Interv Cardiology Med Grp, West Hills, California, United States

    Contact: Study coordinator (Michael Fam) · mfam@elegantrd.com · +1 818 235 7104
    Contact: Principal Investigator (Farhad Rafii)

  • Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States

  • Jacksonville Center for Clinical, Jacksonville, Florida, United States

    Contact: Study coordinator (Theresa Hanburry) · thanburry@encoredocs.com · +1 904 730 0101
    Contact: Principal Investigator (Michael J Koren)

  • K2 Medical Research LLC, Maitland, Florida, United States

  • University of Miami Hospital, Miami, Florida, United States

    Contact: Study coordinator (Maria Alamanzar) · maa3400@miami.edu
    Contact: Principal Investigator (Andrew Bromley)

  • Baptist Health South, Miami, Florida, United States

    Contact: Study coordinator (Ruben Dominguez) · Ruben.Dominguez@baptisthealth.net · +1 786 595 8078
    Contact: Principal Investigator (Adedapo Iluyomade)

  • Inpatient Research Clinical LLC, Miami Lakes, Florida, United States

  • FXM Clin Res Miramar LLC, Miramar, Florida, United States

    Contact: Study coordinator (Raul Hernandez) · raul@eminat.net · 19544301097
    Contact: Principal Investigator (Yaneth Trujillo)

  • Ocala Cardiovascular Research, Ocala, Florida, United States

    Contact: Study coordinator (Arleana Brown) · arleana.brown@morganmmc.com
    Contact: Principal Investigator (Lan Luo)

  • SEC Clinical Research, Pensacola, Florida, United States

    Contact: Study coordinator (Tatum Ramsey) · tramsey@secclinicalresearch.com · +1 850 696 7148
    Contact: Principal Investigator (Robert I Garver)

  • Peace River Cardiovascular Center, Port Charlotte, Florida, United States

    Contact: Study coordinator (Karen Mullinax) · karen@prcvcfl.com · +1 941 629 5356
    Contact: Principal Investigator (David Allan Hotchkiss)

  • University Of South Florida, Tampa, Florida, United States

    Contact: Study coordinator (Amanda Mcnamara) · alett1@usf.edu
    Contact: Principal Investigator (Shone Almeida)

  • FC Site Partners Miami, Winter Park, Florida, United States

    Contact: Study coordinator (Claisha Pruitt) · cpruitt@flourishresearch.com
    Contact: Principal Investigator (Monica Aggarwal)

  • Advocate Lutheran General Childrens Hospital, Park Ridge, Illinois, United States

    Contact: Study coordinator (Marina Kelly) · marina.kelly@aah.org
    Contact: Principal Investigator (Adib Chaus)

  • American Health Network Research Dept, Muncie, Indiana, United States

    Contact: Study coordinator (Stephanie Stewart) · stephanie_stewart@ahni.com · +1 765 213 2876
    Contact: Principal Investigator (Jonathan Condit)

  • American Health Network Research Dept, Muncie, Indiana, United States

    Contact: Study coordinator (Gorgi Leigh Avery) · gorgi_avery@ahni.com
    Contact: Principal Investigator (Andrew Daluga)

  • Cardiovascular Associates Research, Covington, Louisiana, United States

    Contact: Study coordinator (Melinda Accardo) · crc3hch@gmail.com · +1 985 892 2550
    Contact: Principal Investigator (Dale Presser)

  • Omega Clinical Research, Metairie, Louisiana, United States

    Contact: Study coordinator (Tina Messina) · tmessinarn@gmail.com · +1 504 914 8726
    Contact: Principal Investigator (Tuan-Huy Tran)

  • Flourish Research Bowie, Bowie, Maryland, United States

    Contact: Study coordinator (Weemon Reed) · wreed@flourishresearch.com
    Contact: Principal Investigator (Sara Collins)

  • Anderson Medical Research, Ft. Washington, Maryland, United States

    Contact: Study coordinator (Ann-Marie Cobb) · andersonmedicalresearch@gmail.com
    Contact: Principal Investigator (Felton Anderson)

  • Henry Ford Hospital, Detroit, Michigan, United States

    Contact: Study coordinator (Jodi Carter) · jcarte23@hfhs.org · +1 313 916 2721
    Contact: Principal Investigator (Khaled Abdul-Nour)

  • Aa Mrc Llc, Flint, Michigan, United States

    Contact: Study coordinator (Fayyaz Shah) · fshah@aamrc.net
    Contact: Principal Investigator (Ahmed A Arif)

  • MyMichigan Medical Center Midland, Midland, Michigan, United States

    Contact: Study coordinator (Katie Kamyszek) · Katie.kamyszek@mymichigan.org · +1 989 631 2469
    Contact: Principal Investigator (William Roy Felten)

  • AB Clinical Trials, Las Vegas, Nevada, United States

    Contact: Study coordinator (Fungai Siziba-Dubose) · fsdabct@gmail.com · +1 702 804 5900
    Contact: Principal Investigator (Atoya Adams)

  • Overlook Medical Center, Summit, New Jersey, United States

    Contact: Study coordinator (Betty Merveil-Ceneus) · betty.merveil-ceneus@atlantichealth.org
    Contact: Principal Investigator (Robert Fishberg)

  • Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Keishia Rodriguez) · keishia.rodriguez@advocatehealth.org
    Contact: Principal Investigator (Michael Shapiro)

  • The Corvallis Clinic P C, Corvallis, Oregon, United States

    Contact: Study coordinator (Erin Thompson) · erin.thompson@corvallis-clinic.com · +1 541 753 1618#1029
    Contact: Principal Investigator (Daniel P. Barrett)

  • Novartis Investigative Site, Tullahoma, Tennessee, United States

    Contact: Study coordinator (Kayla Nee) · kntcct2@gmail.com · +1 931 393 7831
    Contact: Principal Investigator (Dinesh Gupta)

  • PharmaTex Research LLC, Amarillo, Texas, United States

    Contact: Study coordinator (Salma Villarreal) · sestradaptx@gmail.com · +1 806 355 2581
    Contact: Principal Investigator (David Brabham)

  • Kelsey Seybold Research Foundation, Houston, Texas, United States

    Contact: Study coordinator (Julian Edmonson) · julian.edmonson@kelseyresearch.com · +1 713 791 6989
    Contact: Principal Investigator (Fisayomi Shobayo)

  • Northwest Houston Clinical Research PLLC, Tomball, Texas, United States

    Contact: Study coordinator (Dawn Burns) · dburns@houstonheartcenter.com · +1 281 351 4911
    Contact: Principal Investigator (Shamaila Aslam)

  • Intermountain Medical Center, Murray, Utah, United States

    Contact: Study coordinator (Tyler Winslow) · tyler.winslow@imail.org · +1 801 507 4777
    Contact: Principal Investigator (Jeffrey Anderson)

  • Virginia Heart, Falls Church, Virginia, United States

    Contact: Study coordinator (Deanna Overbeck) · Doverbeck@VirginiaHeart.com · +1 703 766 5920
    Contact: Principal Investigator (Tariq Haddad)

  • Novartis Investigative Site, Yinchuan, Ningxia, China

  • Novartis Investigative Site, Jining, Shandong, China

  • Novartis Investigative Site, Xian, Shanxi, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Béziers, France

  • Novartis Investigative Site, Cholet, France

  • Novartis Investigative Site, Grenoble, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Pessac, France

  • Novartis Investigative Site, Poitiers, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Stuttgart, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Potsdam, Brandenburg, Germany

  • Novartis Investigative Site, Chemnitz, Saxony, Germany

  • Novartis Investigative Site, Leipzig, Saxony, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Bielefeld, Germany

  • Novartis Investigative Site, Gelnhausen, Germany

  • Novartis Investigative Site, Mannheim, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Singen, Germany

  • Novartis Investigative Site, Hong Kong, Hong Kong, Hong Kong

  • Novartis Investigative Site, Hong Kong, Hong Kong

  • Novartis Investigative Site, Ancona, AN, Italy

  • Novartis Investigative Site, Caserta, CE, Italy

  • Novartis Investigative Site, Grosseto, GR, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Rozzano, MI, Italy

  • Novartis Investigative Site, Perugia, PG, Italy

  • Novartis Investigative Site, Pordenone, PN, Italy

  • Novartis Investigative Site, Salerno, SA, Italy

  • Novartis Investigative Site, Legnago, VR, Italy

  • Novartis Investigative Site, The Hague, South Holland, Netherlands

  • Novartis Investigative Site, Enschede, Netherlands

  • Latin Clinical Trial Center Inc, San Juan, Puerto Rico

    Contact: Study coordinator (Gina Velez) · gvelez@lctcpr.com · +1 787 249 4763
    Contact: Principal Investigator (Alex Gonzalez Bossolo)

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Castilleja de la Cuesta, Sevilla, Spain

  • Novartis Investigative Site, A Coruña, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Huelva, Spain

  • Novartis Investigative Site, Las Palmas GC, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Changhua, Taiwan

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Tainan, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Chichester, West Sussex, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Manchester, United Kingdom

  • Novartis Investigative Site, Tyne and Wear, United Kingdom

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)